Although it lowered its outlook for vaccines, including Arexvy, this was more than offset by new revenue contributions from the oncology drug Blenrep and various late-stage pipeline assets.

While two vaccines are available - Abrysvo and Arexvy - the Centers for Disease Control and Prevention doesn't recommend one over the other.

GSK has historically been strong in vaccines and respiratory medicines. But Arexvy, its vaccine against respiratory syncytial virus, suffered a setback when a US immunisation advisory group ...

However, the Vaccines segment experienced a 12% decline in sales, largely due to reduced demand for the RSV vaccine Arexvy. GSK has announced a £2 billion share buyback program over the next 18 ...

following a mandatory swine flu vaccine, Guillain-Barré is also an unexpectedly common adverse event from adenovirus-based COVID vaccines and has cropped up in trials for Pfizer’s Abrysvo and GSK’s ...

After predicting growth in vaccine sales in July of last year, poor performance from GSK’s Respiratory Syncytial Virus vaccine Arexvy led to an overall 4 percent drop in vaccine sales.

GSK’s Arexvy, which became the first RSV vaccine approved in 2023 and protects older adults, reached about $734 million in sales in 2024, down 52% from the previous year, according to the ...

By May 2024, the FDA approved three RSV vaccines for adults. The three FDA-approved RSV vaccines for adults 60 and older are GSK’s AREXVY, Pfizer’s ABRYSVO and Moderna’s mRESVIA. Initially, in June ...

The Moderna vaccine faces stiff competition from RSV vaccines Arexvy and Abrysvo, marketed by GSK and Pfizer, respectively. In the past year, MRNA stock has lost nearly 63%, significantly underper ...

So, the main culprit in GSK's revenue decline was Arexvy, whose sales in the U.S. fell sharply year-on-year, mainly due to increased competition from Pfizer's Abrysvo (PFE), as well as updated ...

GSK’s Arexvy is currently approved for adults aged 60 and above for the prevention of LRTD caused by RSV. The vaccine is also approved for high-risk adults aged 50-59 years. PFE’s Abrysvo ...

Please note that sales of Pfizer’s PFE RSV vaccine, Abrysvo, and GSK plc’s GSK RSV vaccine Arexvy also declined in the fourth quarter. This downtick can be attributed to the restrictive ...